Navigation Links
Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
Date:8/26/2010

om/">http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Statements

Various statements in this release are "forward-looking statements" under the securities laws.  Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements.  Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.  Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's inability to utilize a substantial portion of its prior net operating losses and research and development credits; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's prod
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- Over the next five years, the marijuana industry in the ... that 14 more states will legalize recreational marijuana and two ... legal cannabis grew 74 percent in 2014 to $2.7 billion, ... could grow more than fourfold to $11 billion in the ... marijuana. Cannabiz Mobile Inc. (OTCBB: LGBI) is a ...
(Date:4/17/2015)... 16, 2015 Research and Markets ( ... "Corporate Reputation of Pharma in 2014 - a Perspective ... to their offering. This independent study, funded ... groups with an interest in diabetes on the corporate ... pharma industry as a whole) in 2014. The results ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) has announced ... in 2014 - a Perspective of Mental Health Patient ... For the first time, in 2014, the ... the pharmaceutical industry held by patient groups with an ... organisations representing all therapy areas. - Findings ...
Breaking Medicine Technology:Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3
... Novo Software™, a leading provider of flow cytometry data ... cytometry instruments and reagents, announced today an agreement whereby ... FCS Express™ – to customers in clinical, research and ... FCS Express with every CyFlow® Cube instrument and resell ...
... (OTC Bulletin Board: NEPH ) announced that it ... Administration ("FDA") of the 510(k) application for marketing clearance of ... Nephros submitted a new 510(k) application to market its hemodiafiltration ... Nephros received the initial FDA review of its new 510(k) ...
Cached Medicine Technology:Partec to Distribute FCS Express 4 Flow Cytometry with CyFlow Cube™ Instruments 2Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 2Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 3Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 4
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancesavings.biz has ... insurance plans are cheaper during Spring. , ... auto insurance plan. Drivers should make sure they compare ... their vehicles. Clients can learn more about Spring car ... , Auto insurance quotes are becoming more and ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post explaining how ... , Clients can review important auto insurance quotes online, ... important advantages for clients who need affordable financial security ... have coverage for their vehicles can purchase a policy ... Many agencies offer important discounts and drivers can learn ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has ... "We had to run maintenance on our shipping facilities ... Ramirez, the PR Director. "It disrupted our regular shipping ... are back on track after having completed the maintenance." ... phone systems which has not allowed some calls to ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 PHOENIX, ARIZONA ... County, along with 11 other secure destruction professionals across ... Destruction Specialists (CSDS). He will now display “CSDS” as ... were offered before the National Association of Information Destruction ... and another Grapevine, Texas. Of the 20 people who ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 ERGO-Pedic Products, ... is introducing two new products to help a broader ... back pain relief are the second most common visitors ... first product, designed specifically to help relieve sitting pain. ... Cushion, and thousands of happy customers later, we began ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... suggests it could show who will respond best to ... -- Genetic differences might explain why some multiple sclerosis ... an international study. , Starting with 206 southern European ... the disease, the researchers compared the DNA of patients ...
... enhancements in key genes connected to the p53 regulatory ... by creating additional safeguards in human genes to boost ... could cause cancer or a variety of genetic diseases, ... Hospital Medical Center writes in the Jan. 22 Proceedings ...
... a,statement by Reverend Carlton W. Veazey, President and CEO ... 35th anniversary of Roe v. Wade, our country is ... be safe, legal, and available,if and when it is ... the ,fetal personhood, initiatives and outright abortion bans,being promoted ...
... Inc, (TSX:,DAX) (NASDAQ: DRAX ) has received approval ... Normal Course Issuer Bid (NCIB) to,purchase up to 4,072,054 ... shares in the public float as at January 14, ... DRAXIS were issued and,outstanding., Purchases may begin on ...
... Ross J. Horsburgh Brings 20 Years of Pharmaceutical and CRO ... in Asia/Pacific Region to Key Leadership Role, ... a,leading, global full-service clinical research organization (CRO), today,announced Dr. Ross ... Development - Asia/Pacific. In this role, he will lead the,company,s ...
... be treated with Traditional Chinese medicine (TCM). Some say ... a research group in China had found TCM can ... suppress tumor cell growth and regulate tumor cell invasion ... 7, 2008 in the World Journal of Gastroenterology ...
Cached Medicine News:Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 2Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 3Health News:Evolution of human genome's 'guardian' gives people unique protections from DNA damage 4Health News:Statement of the Reverend Carlton W. Veazey, President and CEO of the Religious Coalition for Reproductive Choice, on the 35th Anniversary of Roe v. Wade 2Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 2Health News:Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion 3Health News:How does Fu-Zheng-Jie-Du-Decoction act on PTEN expression in hepatocellular carcinoma? 2
... The ADVIA 1650 has minimal requirements for ... reagent consumption (as low as 80 L/test) ... maximizing management efficiency. , , Outstanding productivity ... throughput of up to 1650 tests/hour provide ...
... designed with a whole new level of ... to 2,000 tests per hour-a higher level ... higher level of efficiency and patient turn-around ... that allows for easy to use multi-view ...
... Standardized technology. Reagents, calibrators and controls ... minimize inventory, purchasing, and training costs. ... care system. Automated sample handling. 70 ... samples. 2-35 ml sample volumes. Intermix ...
The Advia IMS integrates a full menu of both immunoassay and chemistry tests....
Medicine Products: